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ABSTRACT 
Background: Hepatocellular carcinoma (HCC) is a common clinical problem all over the world.  
Fucosylated-hemopexin (Fuc-Hpx) is a newly reported glycoprotein for the diagnosis of HCC, 
however, its clinical implication is not referred.  The aim of this study was to elucidate the clinical 
utility of Fuc-Hpx in Japanese patients with HCC.   
Methods: The sera from 331 HCC patients, 45 with liver cirrhosis (LC), 85 with chronic hepatitis 
(CH), and 22 healthy people were examined for the expression of Fuc-Hpx; the level was compared 
with clinical parameters as well as hemopexin (Hpx) expression.  The expressions of Fuc-Hpx in 12 
HCC tissues and corresponding adjacent non-cancerous liver tissues were also examined.  
Results: No correlation was observed between Hpx and Fuc-Hpx level.  The median Fuc-Hpx 
levels in healthy people, CH, LC, and HCC patients were 3.8, 3.7, 6.1, and 7.6 AU/ml, respectively 
(CH vs. LC, p=0.002; CH vs. HCC, p<0.001; LC vs. HCC, p=0.02).  Multivariate analysis revealed 
that low albumin, low prothrombin time, and the presence of HCC were significantly correlated 
with high Fuc-Hpx (p=0.013, p=0.001, and p<0.001, respectively).  Among the HCC patients, 
albumin was correlated with high Fuc-Hpx; however, none of the tumor factors, such as tumor size, 
tumor number, and tumor stage, was correlated with Fuc-Hpx level.  The expression of Fuc-Hpx in 
cancer tissue was not different from that in non-cancerous tissue.  
Conclusions: Fuc-Hpx is a valuable biomarker for HCC but it might be a marker for 
hyper-carcinogenic liver rather than a marker for tumor-bearing.  
Keywords: Fucosylated-hemopexin, Hepatocellular carcinoma, Glycosylation, Biomarker, 
hyper-carcinogenicity, 
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INTRODUCTION 
HCC is the fifth most common cancer and its very poor prognosis makes it the third 
leading cause of cancer death worldwide.1, 2  HCC accounts for over 90% of common primary liver 
cancer in Japan.  More than 80% of HCC cases develop in patients suffering from long-lasting viral 
hepatitis.  Recently, rising rates of diabetes, obesity, and nonalcoholic steatohepatitis (NASH) have 
become increasingly important risk factors of future HCC incidence trends globally, particularly in 
developed countries.3, 4  Although HCC without hepatitis virus infection, which is difficult to 
survey, is increasing and the percentage of cases with viral hepatitis is decreasing in Japan, the 
majority of HCC patients (over 80%) still suffer from either hepatitis C or hepatitis B virus 
infection.5  Many of these patients were under surveillance programs for the diagnosis of HCC, 
resulting in smaller tumor size at diagnosis. 
While modalities of imaging diagnoses have been improving and therapeutic options have 
progressed, a major problem in HCC surveillance is the lack of reliable biomarkers.4  
Alpha-fetoprotein (AFP) is the best available biomarker with high sensitivity for HCC surveillance, 
but the low specificity of AFP led the American Association for the Study of Liver Disease 
(AASLD) Practice Guideline Committee to recommend that surveillance has to be based on 
ultrasound examination.6  Des-γ-carboxy prothrombin (DCP) is used widely as an HCC biomarker 
in Japan, but it is not popular in other countries including the United States.  DCP is more closely 
related to tumor size with high sensitivity in the diagnosis of large HCC than AFP, but the sensitivity 
is low for the diagnosis of small HCC.7  It is known that the fucosylation of glycoprotein often 
emerges during carcinogenesis.8-15  The fucosylated AFP (AFP-L3) was highly specific and 
correlated with biological malignancy and prognosis of HCC patients.16-19  Recent glycan analysis 
demonstrated the increasing fucosylation of serum glycoproteins, not only AFP but also haptoglobin, 
fetuin A, hemopexin (Hpx), kininogen, α-1 antitrypsin, and Golgi protein 73 (GP73) with the 
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development of HCC.8, 15 
Hpx is a 60-kDa glycoprotein that is one of the acute-phase reactant proteins.  Besides its 
classical functions, such as binding and transportation of free heme in peripheral blood, a wide range 
of other properties of the hemopexin molecule have been described, such as antioxidant activity.20  
Hpx is produced in the liver and secreted in serum. A report from the United States demonstrated 
that the fucosylated form of hemopexin (Fuc-Hpx) was a good serum marker for HCC and its 
capacity for the diagnosis of HCC was superior to that of AFP.8, 9, 21  However, the profile of 
glycosylation is known to be different by age, race, or resident country.22  In addition, HCC 
surveillance has become popular, so the size of HCC at diagnosis is smaller in Japan than in other 
countries.23, 24  Thus, the aim of this study is to evaluate the clinical utilities of Fuc-Hpx in Japanese 
HCC patients.   
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MATERIAL & METHODS 
Human subjects 
Human serum samples were obtained from newly developed HCC patients (n=331), those 
with chronic hepatitis (CH: n=85), or those with liver cirrhosis (LC: n=45), who were admitted to 
Okayama University Hospital between 2002 and 2009, as well as from healthy volunteers (n=22).  
The serum was collected at the time of admission, meaning that no intervention had been performed.  
The characteristics of the patients are summarized in Table 1.  Healthy subjects did not have a past 
history of liver disease, cancer, or metabolic or hormone disorder that required medication.  Age is 
shown as median and interquartile range.  The median age of HCC patients was older than that of 
others (p<0.001).  For etiology, patients with hepatitis B virus surface antigen positivity were 
classified HBV, and those with hepatitis C virus antibody were classified as HCV.  Alcohol-induced 
liver injury, NASH, autoimmune hepatitis, or liver disease of unknown origin were classified as 
others.  Over 80% of the patients suffered from viral infection in both the HCC and the non-HCC 
groups, and hepatitis C viral infection was more prevalent in HCC patients than in non-HCC patients 
(73% vs. 49%, p<0.001).  The changes of Fuc-Hpx between before and after curative treatments of 
HCC were examined in 21 cases.  Nine cases were treated by local curative treatments (5 surgical 
resection and 4 radiofrequency ablation).  The others were treated by liver transplantation. 
HCC tissue samples and the corresponding adjacent liver tissue samples were obtained from 
12 patients who received liver transplantation.  Informed consent was obtained from all patients, 
and the study protocol conformed to the ethical guidelines of the World Medical Association 
Declaration of Helsinki and was approved by our institutional review board. 
 
Diagnosis of HCC 
In accordance with the American Association for the Study of Liver Disease (AASLD, 2005) 
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Practice Guidelines, we confirmed the diagnosis of HCC by at least 2 dynamic imaging modalities.  
Typical findings were confirmed as hyperattenuation at the arterial phase and hypoattenuation at the 
portal phase in dynamic computed tomography (CT) or magnetic resonance imaging (MRI), and 
tumor staining on angiography.  The nodules without these findings were diagnosed by histological 
examination via US-guided, fine-needle biopsy.  Stage was based on the General Rules for the 
Clinical and Pathological Study of Primary Liver Cancer.  The diagnosis of CH and LC was based 
on liver histology, or clinical and laboratory data including the findings of ultrasound, CT or MRI. 
 
Sample preparation from human liver tissues 
Human liver samples were extracted from 50 mg of frozen tissues. Briefly, samples were 
homogenized with 250 μl reagent mixed CelLyticTM-MT (SIGMA-ALDRICH, St. Louis, USA) 
containing protease inhibitor.  The lysed samples were centrifuged for 10 minutes at 4°C, 
12,000-20,000 X g, to pellet the tissue debris.  The supernatant was harvested in a clean tube and 
used for the following studies.  The protein’s concentration in each sample was measured by the 
Bradford method.  
 
Measurement of Hpx 
Serum Hpx concentrations were measured by enzyme-linked immunosorbent assay 
(ELISA).  We used the AssayMax Human Hemopexin ELISA kit (ASSAYPRO, St. Charles, USA).  
The samples were measured in duplicate according to the manufacturer’s instructions.  A 
microplate reader (BIO-RAD Model680, BIO-RAD Laboratories, Tokyo, Japan) was used for 
reading absorbance at 450 nm.  
 
Lectin ELISA for Fuc-Hpx 
Fucosylated-hemopexin and HCC  7 
 
7 
 
We performed lectin-ELISA for quantitative analysis of Fuc-Hpx in accordance with the 
method reported by Metha et al. with some modification.9  Briefly, the rabbit anti-human 
hemopexin antibody (ASSAYPRO, St. Charles, USA) was incubated with 10 mmol/L sodium 
periodate to remove the fucosylation of the captured antibody at 4°C for 1 hr. under dark conditions.  
An equal volume of ethylene glycol was added and the oxidized antibody was diluted to a 
concentration of 10 μg/ml with sodium carbonate buffer (pH9.5).  1 μg of antibody was added to 
each well of the ELISA plate and incubated overnight at 4°C.  The plate was washed 5 times with 
0.1% Tween 20/PBS7.4 (PBS-T) and then blocked overnight with 3% bovine serum albumin/PBS.   
For analysis, 50 μl of serum was diluted in 50 μl of PBS with 1 μl of Immunoglobulin 
Inhibiting Reagent (BIORECLAMATION, New York, USA) and incubated at room temperature for 
45 minutes.  The samples were added to the plate and incubated at 37°C for 1 hr, followed by 
washing with lectin incubation buffer (10 mM Tris pH8.0, 0.15 M NaCl, 0.1% Tween20) 5 times.  
After that, AAL lectin (VECTOR LABORATORIES, Burlingame, USA) diluted 250 times by lectin 
incubation buffer was applied and incubated at room temperature for 1 hr.  After 5 washes with 
PBS-T, AP-streptavidin (VECTOR) diluted 1000 times by PBS was applied and incubated at room 
temperature for 1 hr.  After washing 5 times, color was developed using phosphatase substrate 
(KPL, Baltimore, USA), and the optical density (OD) at 630 nm was measured.  The concentration 
is expressed as arbitrary unit (AU) based on the relative concentration against a standard HCC 
sample and normal stock serum.  Control curve of lectin-ELISA was shown at Figure 1. 
 
Statistical analysis 
JMP (version 8.02) software package (SAS Institute, Cary, North Carolina, USA) was used 
for the analyses.  Continuous variables are shown as median and interquartile range.  The 
Wilcoxon rank sum test was used to compare the continuous data and the chi-squared test was used 
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to compare categorical data.  Statistical significance was set at p< 0.05.  Univariate analysis 
was performed in all patients except healthy volunteers to identify the potential factors 
correlated with Fuc-Hpx in liver diseases.  Variables at p<0.05 in the univariate 
analysis were further analyzed to identify independent factors correlated with Fuc-Hpx 
by multivariate analysis.  The variables used in the analysis included age, sex, etiology, 
presence of HCC, platelet count (Plt), prothrombin time (PT), albumin (Alb), total 
bilirubin (T-Bil), aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
and Child-Pugh grade.  For the analysis in HCC patients, tumor markers such as AFP, 
AFP-L3, DCP, tumor size, tumor number, presence of portal vein tumor thrombosis (Vp), 
and tumor stage (Stage) were added.  The optimal cut-off values of most variables were 
set at approximate values of medians.  Those of AFP, AFP-L3, and DCP were 20 ng/ml, 
10%, and 40 mAU/ml, respectively.  Paired t-test was used for the analysis of Fuc-Hpx 
expression levels between HCC and adjacent liver tissues.  Correlation analysis was verified at r2 
value by Pearson correlation coefficient.  Diagnostic abilities in differentiating HCC from liver 
disease without HCC were evaluated using the areas under the Receiver Operating Characteristic 
(ROC) curve (AUROC).  Sensitivity, specificity, and accuracy were analyzed by McNemar test, 
and positive predictive value (PPV) and negative predictive value (NPV) were analyzed by Fisher’s 
exact test.  All test were two sided between Fuc-Hpx and another marker, and p<0.05 was 
considered significant. 
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RESULTS 
Relationship between serum Hpx and Fuc-Hpx 
To determine the effect of Hpx concentration on Fuc-Hpx level, we measured both Hpx and 
Fuc-Hpx expressions in 18 samples simultaneously (Figure 2).  No correlation was observed 
between Hpx and Fuc-Hpx (p=0.89).  The level of Hpx was not significantly different between 
non-HCC (median 648 AU/ml, range 488-750) and HCC groups (772 AU/ml, 483-1022, p=0.16), 
whereas Fuc-Hpx level was higher in HCC group (6.8 AU/ml, range 4.9-11.0) than in non-HCC 
group (2.6 AU/ml, range 0.9-4.8, p<0.001).  Because total Fuc-Hpx level was closely correlated 
with the percentage of Fuc-Hpx (R2=0.6, p<0.001) and no difference of AUROC of total and 
percentage of Fuc-Hpx was observed in this study population (0.84 and 0.77, respectively), we used 
total Fuc-Hpx level in the following analysis. 
 
Serum Fuc-Hpx level in liver diseases  
To confirm the Fuc-Hpx expression in various liver diseases, we measured it in large 
populations.  The median value in HCC group (n=331) was 7.6 AU/ml (range 5.6-10.8), which was 
significantly higher than that of non-HCC group (n=130, median 4.6 AU/ml, range 2.5-7.1, p<0.001).  
A progressive increase of Fuc-Hpx was observed from that of healthy controls (median 3.8 AU/ml, 
range 0.1-5.8) through CH (3.7 AU/ml, 1.9-6.2) to LC (6.1 AU/ml, 4.1-8.9).  Significant difference 
was observed between HCC group and LC (p=0.02) or CH group (p<0.001), and between LC and 
CH groups (p=0.002), but no difference was observed between CH group and healthy subjects 
(Figure 3).  We examined Fuc-Hpx level in patients with or without HCC with the same liver 
function.  The median was 7.7AU/ml (range 5.4-10.5) in HCC group, which was significantly 
higher than that in non-HCC group (median 3.9 AU/ml, range 2.1-6.7, p<0.001) in Child-Pugh grade 
A patients.  In Child-Pugh grade B/C patients, no difference was observed between the groups, and 
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the median was 7.8 AU/ml (range 6.2-11.1), and 6.6 AU/ml (range 5.5-11.2) in HCC group and in 
non-HCC group respectively.  We measured to compare Fuc-Hpx levels in 21 HCC cases before 
and after curative therapy.  Fuc-Hpx levels in all 9 cases but one who received local curative 
treatments did not decrease after the treatments.  The median of Fuc-Hpx level before and after 
the treatments were 5.23 and 6.77 AU/ml, respectively.  On the other hand, in 9 out of 12 HCC 
cases who received liver transplantation, the median of Fuc-Hpx level significantly decreased from 
10.2 to 4.87 AU/ml (p=0.02).  Significant difference was observed between local curative treatment 
and liver transplantation (p=0.001). 
 
Factors correlated with serum Fuc-Hpx 
We evaluated the relationship between serum Fuc-Hpx and clinical parameters in patients 
with liver diseases (Table 2).  Fuc-Hpx in elderly patients and HCV-infected patients was high.  
High AST (≥40 IU/l) and T-Bil (≥1.0 mg/dl), and low Plt (≤10 ×104/μl), PT (<100 %) and Alb 
(≤3.5 g/dl), were also correlated with high serum Fuc-Hpx level.  In addition, the presence of HCC 
was significantly associated with high Fuc-Hpx (p<0.001).  On multivariate analysis, low Alb, low 
PT, and the presence of HCC were significantly correlated with high Fuc-Hpx (p=0.013, p=0.001, 
and p<0.001, respectively).  
The relationship between Fuc-Hpx and tumor factors in combination with three variables 
that showed correlation with Fuc-Hpx on multivariate analysis was examined in HCC patients (Table 
3).  None of the tumor factors such as tumor size, tumor number, Vp, or STAGE was correlated 
with Fuc-Hpx level.  Fuc-Hpx was high in patients with high DCP (≥40 mAU/mL), while AFP and 
AFP-L3 were not correlated with Fuc-Hpx.  On multivariate analysis, Alb was the only factor 
correlated with serum Fuc-Hpx level (p=0.027). 
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Utility of Fuc-Hpx for the diagnosis of HCC 
The accuracy, sensitivity, and specificity of Fuc-Hpx for the diagnosis of HCC were 69%, 
71%, and 63% at a cut-off of 5.95 AU/ml, respectively (Table 4).  The diagnostic accuracies of AFP 
and DCP in the same serum samples were 56% and 58%, sensitivities were 46% and 47%, and 
specificities were 87% and 91% at cut-offs of 20 ng/ml and 40.0 mAU/ml, respectively.  We 
showed ROC curve of three individual markers in Figure 4.  AUROC of Fuc-Hpx for the diagnosis 
of HCC was 0.739, which was inferior to those of AFP (0.791) but was superior to those of DCP 
(0.723). 
The levels of AFP and DCP gradually increased as the stage progressed, but no correlation 
was observed between Fuc-Hpx and the stage.  The sensitivity of Fuc-Hpx were superior to those 
of the others in both stage I and >stage II patients.  The clinical utility of Fuc-Hpx was equivalent 
in both stage I and >stage II patients as well as AFP.  AUROC was statistical significant superior 
to DCP in stage I.   
The sensitivities of Fuc-Hpx+AFP and Fuc-Hpx+DCP were 84% and 74%, respectively, 
and the specificities were 66% and 71%, respectively.  Sensitivity was improved, whereas 
specificity was not improved by combination with AFP or DCP. 
 
Fuc-Hpx expression in liver tissue 
The expression of Fuc-Hpx in HCC tissue was higher than that in adjacent non-cancerous 
liver tissue in 4 out of 12 HCC patients, almost equal in one patient, and lower in 7 patients.  
Median Fuc-Hpx level in HCC tissue was 6.5 AU/ml and was 7.0 AU/ml in adjacent non-cancerous 
tissue. The difference between them was not statistically significant (Figure 5). 
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DISCUSSION  
Several tumor markers of HCC have been identified, but there is no evidence indicating that 
the detection of HCC by these markers precedes clinical imaging diagnosis.  However, the 
diagnostic accuracy of the radiological tools is tumor-size-dependent and this approach is 
expensive.25  Moreover, ultrasound examination is affected by the skill of individual operators.  
Therefore, it is necessary to find non-invasive, reliable markers for detecting or predicting HCC. 
The expression of Fuc-Hpx increased according to the progression of liver disease from 
hepatitis, cirrhosis, to HCC, and albumin, PT, and the presence of HCC were major factors to 
determine the expression level.  However, we did not observe any correlations between Fuc-Hpx 
and tumor factors such as tumor size or tumor number.  The result is quite different from those of 
conventional tumor markers such as AFP and DCP.  From the analysis of the expression in liver 
tissues, Fuc-Hpx was produced not only in HCC but also in non-cancerous tissue, meaning that 
Fuc-Hpx might be a biomarker for hyper-carcinogenic liver rather than a marker for tumor-bearing.  
Recently, glycoproteomics and glycomics have been focused on as a post-genomic research 
field to find diagnostic markers.26, 27  Glycosylation is involved in both physiological and 
pathological events, such as cell growth, migration, differentiation, and tumor invasion.  In 
particular, fucosylation of N-glycan is well known as one of the changes during carcinogenesis of 
various cancers.8, 14, 15, 28  There are several putative mechanisms of elevation of fucosylated 
proteins in cancers.  A tumor marker of hepatocellular carcinoma, AFP-L3, was produced by 
core-fucosylation of AFP by α-1,6-fucosyltransferase (Fut8), which is overexpressed in advanced 
liver diseases.  However, high expression of Fut8 was also observed in non-cancerous liver 
cirrhotic tissues as well as HCC tissues.29  α-1,6-fucosylated proteins are normally rare in the blood 
and are enriched in the bile by proper balance of two secretion pathways of glycoproteins; one is 
sorting to an apical surface of hepatocytes followed by secretion into bile ducts and the other is 
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sorting to the basolateral surface followed by secretion into blood vessels.13  If hepatocytes become 
depolarized in hepatocarcinogenesis, these normal secretion pathways cannot work and, thus, 
fucosylated proteins are elevated in the blood.30 
Several reports have been published dealing with the utility of Fuc-Hpx for the diagnosis of 
HCC.8, 9, 21  They reported that Fuc-Hpx is superior to AFP, which has been a standard marker for 
the detection of HCC.  Communale et al. reported that the sensitivity and specificity of Fuc-Hpx for 
the diagnosis of HCC were high (both 92%) and AUROC curve for Fuc-Hpx was 0.951.  In our 
study, the diagnostic ability in Japanese patients was inferior to the data described above.  In 
previous report, they analyzed 72 HCC patients and 280 patients without HCC; however, 248 out of 
280 were non-cirrhotic patients including 20 healthy control.  AUROC decreased to 0.8665 when 
only cirrhotic patients were used as control.  We did not include healthy control for AUROC 
analysis so that the difference of the liver function in non-HCC patients might be one of the reasons 
for the difference of AUROC between the studies.   In addition, the race was different, the median 
age was higher, and the etiology was different; hepatitis virus infection was a major cause of liver 
injury in our research, while alcoholism was the main etiology in previous reports.  Although it is 
not clear whether these differences affect the diagnostic utility, it is possible that albumin and PT, 
which are factors correlated with Fuc-Hpx expression, are different between the studies, which were 
not precisely indicated in other reports.  Despite the differences, Fuc-Hpx expression in HCC 
patients was high in both studies, indicating that Fuc-Hpx is an effective biomarker for HCC.   
Although serum Fuc-Hpx increased in HCC patients, the expression level was not 
correlated with any tumor factors.  Furthermore, Fuc-Hpx levels did not decrease except one case 
by surgical resection or RFA.  On the other hand, 9 out of 12 cases who received liver 
transplantation, which replaced the hyper-carcinogenic liver with the normal liver, Fuc-Hpx level 
decreased by the treatment.  The result indicated that the major source of Fuc-Hpx in blood is 
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non-cancerous liver tissue although it might be secreted from HCC by the mechanism described 
above.  Scarce correlation with tumor factors is a disadvantage as a conventional tumor marker.  
Generally, annual incidence of Hepatocellular carcinoma (HCC) from liver cirrhosis (LC) is known 
to be 4~8%.  On the other hand, the recurrence rate of HCC is reported at an annual rate of 20 %, 
indicating tumor-baring liver is hyper-carcinogenic.  We interpreted that the difference of Fuc-Hpx 
between LC and HCC might correspond to hyper-carcinogenic status mentioned above.  We 
inferred that high level of Fuc-Hpx might not be shown under the existence of HCC and be shown 
under the hyper-carcinogenic liver.  We could not refer in this study how effective Fuc-Hpx was as 
a hyper-carcinogenic marker because we did not prospectively examine.  If we assumed that 
AUROC for the diagnosis of HCC is a surrogate marker of hyper-carcinogenicity, the ability of 
Fuc-Hpx (0.73) was higher than those of albumin, platelet count and Child-Pugh grade (0.53, 0.66, 
and 0.67, respectively) 
In this study, we demonstrated that Fuc-Hpx could be an effective biomarker of HCC.  
Future prospective research is necessary to verify the utility of Fuc-Hpx as a marker for 
hypercarcinogenic liver.  
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FIGURE LEGENDS 
Figure 1. Control curve of lectin-ELISA 
The concentration is expressed as arbitrary unit (AU) based on the relative concentration against 
control curve. 
 
Figure 2. Relationship between serum hemopexin and fucosylated-hemopexin  
The data of HCC and non-HCC are plotted by closed circles and open circles, respectively.  No 
correlation was demonstrated between serum Hpx and Fuc-Hpx in both groups.  
 
Figure 3.  Serum fucosylated-hemopexin concentration  
Serum Fuc-Hpx level increased according to the progression of the liver diseases. 
 
Figure 4. Receiver operating characteristic curve of 3 tumor makers of hepatocellular 
carcinoma 
AUROC of Fuc-Hpx for the diagnosis of HCC was 0.739, which was inferior to those of AFP 
(0.791) but was superior to those of DCP (0.723). 
 
Figure 5. Fucosylated-hemopexin expression in liver tissue  
Fuc-Hpx expressions in HCC tissues and corresponding adjacent non-cancerous liver tissues are 
shown.  Closed circles indicate that Fuc-Hpx was lower in cancer tissue than in non-cancer tissue.  
Closed triangles indicate that Fuc-Hpx expression was higher in cancer tissue.  Closed squares 
indicate that the expression was at the same level in both tissues. 
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Table 1. Baseline characteristics 
Disease  
Healthy 
control 
 non-HCC 
    CH          LC 
HCC  p value  
 Number of patients 22 85 45 331  
 Age (years)  65 (60-71) 50 (41-55) 59 (48-66) 71 (64-76) <0.001 
 Sex  Male (%) 72 61 71 66 N.S. 
 Etiology   (%) 
  HBV/HCV/others 
 36/ 60/ 4 29/ 29/ 42 15/ 73/ 14 <0.001 
 Child-Pugh grade 
A / B or C (%)  
 94/ 6 53/47 79/ 21 <0.001 
 Stage 
I/II/III/IV (%)  
   31/35/20/14  
 
CH, chronic hepatitis; LC, liver cirrhosis; HCC, hepatocellulra carcinoma; HBV, positive for 
hepatitis B virus surface antigen; HCV, positive for hepatitis C virus antibody; others, 
alcohol-induced liver injury, NASH, autoimmune hepatitis, or liver disease of unknown origin.  
 
Statistical significance was set at p< 0.05. 
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Table 2. Fucosylated-hemopexin expression in patients with liver diseases  
 
Variables  
 Fuc-Hpx (AU/ml) 
Univariate 
p-value 
Multivariate
p-value 
Age (years)  ≤ 65 
> 65 
6.2 (3.5-9.0) 
7.5 (5.3-10.8) 
<0.001 0.600 
Sex  Male  
Female  
7.2 (4.5-10.2) 
6.8 (4.5-9.7) 
0.690  
Etiology  HBV  
HCV  
others  
6.3 (4.1-9.8) 
7.4 (4.8-10.4) 
6.2 (3.6-8.8) 
0.025 0.410 
Diagnosis non-HCC 
HCC 
4.6 (2.5-7.1) 
7.6 (5.6-10.8) 
<0.001 
 
<0.001 
 
Plt (×104/μl)  > 10  
≤ 10  
6.6 (3.9-9.8) 
8.1 (5.3-10.4) 
0.002 0.800 
PT (%)  ≥ 100  
<100 
6.3 (4.0-9.4) 
7.9 (5.6-11.0) 
<0.001 
 
0.001 
Albumin (g/dl) > 3.5 
≤ 3.5 
5.8 (3.3-9.0) 
8.1 (6.3-11.1) 
<0.001 
 
0.013 
T-Bil (mg/dl) < 1 
≥ 1 
6.7 (4.0-9.8) 
7.3 (5.3-10.5) 
0.031 0.990 
AST (IU/l) < 40 
≥ 40 
5.3 (2.8-8.4) 
7.4 (5.4-10.3) 
<0.001  
  
ALT (IU/l) < 40 
≥ 40 
6.5 (4.0-9.4) 
7.0 (4.8-10.0) 
0.100  
Child-Pugh grade A 
B＋C 
6.7 (4.2-9.8) 
7.7 (5.8-11.1) 
0.004  
3 
 
Abbreviations of etiology are the same as those indicated in Table 1. Fuc-Hpx, 
fucosylated-hemopexin; HCC, hepatocellular carcinoma; Plt, platelet count; PT, prothrombin time; 
T-Bil, total bilirubin ; AST, aspartate aminotransferase; ALT, alanine aminotransferase 
Statistical significance was set at p< 0.05. 
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Table 3. Relationship between clinical parameters and fucosylated-hemopexin in HCC patients 
Variables  
 Fuc-Hpx (AU/ml) 
Univariate 
p-value 
Multivariate
p-value 
Albumin (g/dl) > 3.5 
≤ 3.5 
7.1 (4.5-10.3) 
8.1 (6.4-11.2) 
<0.001 0.027 
PT (%)  ≥ 100  
< 100 
7.2 (5.0-9.8) 
8.3 (6.1-11.4) 
0.004 
 
0.053 
AFP (ng/ml) < 20 
≥ 20 
7.5 (5.0-10.5) 
7.8 (6.0-10.9) 
0.083  
AFP-L3 (%) < 10 
≥ 10 
7.6 (5.5-10.4) 
7.8 (6.1-11.2) 
0.379  
DCP (mAU/ml ) < 40 
≥ 40 
7.4 (5.0-10.2) 
8.1 (6.0-11.2) 
0.021 0.063 
Tumor size (mm)  
            
< 20 
≥ 20 
7.4 (5.5-10.1) 
8.0 (5.5-11.2) 
0.190  
Tumor number  single  
multiple  
7.4 (5.0-10.4) 
7.7 (6.1-10.9) 
0.230  
Vp yes 
no 
7.6 (5.5-10.4) 
7.7 (4.6-11.0) 
0.800  
Stage I＋II 
III＋IV 
7.5 (5.3-10.2) 
7.7 (5.6-11.1) 
0.420  
 
HCC, hepatocellular carcinoma; Fuc-Hpx, fucosylated-hemopexin; PT, prothrombin time; AFP, 
alpha-fetoprotein; AFP-L3, fucosylated AFP; DCP, des-γ-carboxy prothrombin 
Statistical significance was set at p< 0.05. 
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Table 4. Utilities of tumor markers for the diagnosis of HCC 
 
  Fuc-Hpx AFP DCP 
All stage AUROC 
Sensitivity (%) 
Specificity (%) 
Accuracy (%) 
PPV (%) 
NPV (%) 
0.739 
71 
63 
69 
83 
46 
0.791 
  46** 
  87*: 
56 
91 
36 
0.723 
  47** 
  91** 
58 
94 
37 
Stage  I AUROC 
Sensitivity (%) 
Specificity (%) 
Accuracy (%) 
PPV (%) 
NPV (%) 
0.720 
75 
63 
69 
63 
75 
0.785 
  45** 
  87** 
67 
76 
63 
 0.599* 
  28** 
  91** 
60 
76 
56 
> Stage II AUROC 
Sensitivity (%) 
Specificity (%) 
Accuracy (%) 
PPV (%) 
NPV (%) 
0.737 
71 
63 
69 
83 
46 
0.802 
  46** 
  87** 
56 
91 
36 
0.785 
 57* 
  91** 
68 
93 
51 
 
HCC, hepatocellular carcinoma; Fuc-Hpx, fucosylated-hemopexin; AFP, alpha-fetoprotein; DCP, 
des-γ-carboxy prothrombin; AUROC, areas under the receiver operating characteristic curve; PPV, 
positive predictive value; NPV, negative predictive value 
*Statistically difference between Fuc-Hpx and the other marker in the given group (p <0.05). 
** Statistically difference between Fuc-Hpx and the other marker in the given group (p <0.001). 
